|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Chronic hepatitis C and Crohn's disease: nosocomial infection treatment with PEG-interferon plus ribavirin.
|
16883071 |
2006 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Chronic hepatitis C (CHC) patients achieving rapid virological response (RVR) on PEG-IFN/ribavirin (P/R) therapy have high chance of sustained virological response (SVR).
|
23874444 |
2013 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
PEG-IFN-alpha(2a) (40 kDa) is expected to improve the efficacy and tolerability of treatment for chronic hepatitis C.
|
12667117 |
2003 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
PEG-IFN-alfa 2b 1.5 microg/kg once weekly is the optimal dosing frequency for patients with chronic hepatitis C with predominantly genotype 1 infection.
|
15952104 |
2005 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
A strong association between single nucleotide polymorphisms (SNPs) of IL28B and treatment outcomes of pegylated interferon-α (PEG IFNα) and ribavirin (RBV) has been shown in chronic hepatitis C (CHC) patients with genotype 1.
|
24102823 |
2014 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 187 patients with chronic hepatitis C received PEG IFN-α/ribavirin or natural IFN-β/ribavirin therapy.
|
22554247 |
2012 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 346 chronic hepatitis C (CHC) patients who finished the 48-week pegylated interferon-alpha and ribavirin (PEG IFN-α/RBV) treatment were enrolled in this study.
|
29654010 |
2018 |
|
Hepatitis C, Chronic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
After in vitro stimulation with IFNalpha, CD56(dim) NK cells from patients who had responded to PEG-IFNalpha therapy expressed higher levels of TRAIL than cells from patients with chronic hepatitis C. TRAIL expression, ex vivo, was inversely correlated with HCV-RNA levels during the early phase of PEG-IFNalpha therapy.
|
20334827 |
2010 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the anti-hepatitis C virus (HCV) effect of statins in vitro and clinical efficacy of fluvastatin combined with Pegylated interferon (PEG-IFN)/ribavirin therapy for chronic hepatitis C (CHC) have been reported, the details of clinical presentation are largely unknown.
|
22989264 |
2013 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although, the treatment of chronic hepatitis C (CHC) greatly improved with the use of direct antiviral agents, pegylated-interferon (PEG-IFN) plus ribavirin remains an option for many patients, worldwide.
|
25844942 |
2015 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Attempt to create simple practical algorithm for prospective assessment of PEG interferon/ribavirin related treatment response in individuals with chronic hepatitis C (CHC) basing on the risk factors defined prior to the treatment initiation.
|
22130295 |
2011 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Current guidelines recommend that patients with genotype 2 (G2) and 3 (G3) chronic hepatitis C be treated with pegylated interferon (PEG-IFN) plus low doses of ribavirin (800 mg/day) for 24 weeks, resulting in a sustained virological response (SVR) rate of approximately 80%.
|
21205136 |
2011 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Current standard-of-care antiviral treatment for patients with chronic hepatitis C is combination therapy with pegylated interferon (PEG-IFN) alfa plus ribavirin.
|
18363672 |
2008 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Data concerning the efficacy of PEG-IFN alpha 2a plus ribavirin treatment in treatment-naive, genotype 4-infected chronic hepatitis C (CHC) patients from Europe are limited.
|
19413697 |
2009 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Fifteen treatment-naive patients with chronic hepatitis C infection (genotypes 1, 2, 3, and 4) underwent PEG-IFNα-2b/ribavirin combination therapy.
|
20827759 |
2010 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genotype 1 (G1) chronic hepatitis C (CHC) patients achieving a rapid virological response (RVR) on pegylated interferon (PEG-IFN) plus ribavirin have a high chance of sustained virological response (SVR), influenced by IL28B status, viral load, fibrosis and insulin resistance.
|
22505587 |
2012 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy.
|
24777626 |
2014 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we describe SVR in a 67-year-old woman whose PEG-IFN/RBV combination therapy for chronic hepatitis C with a high viral load of serum HCV RNA, genotype 1b, was discontinued after 16 weeks because of the onset of PEG-IFN plus RBV-induced acute pancreatitis.
|
19246919 |
2009 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
In total, 126 consecutive chronic hepatitis C (CHC) patients who received combined PEG-IFN and RBV therapy were included.
|
19817959 |
2010 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Locally produced PEG-IFN in Iran is safe and effective in treatment-naïve chronic hepatitis C.
|
20597564 |
2010 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Maintenance of T1 response as induced during PEG-IFNalpha plus ribavirin therapy controls viral replication in genotype-1 patients with chronic hepatitis C.
|
16262527 |
2005 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Many studies have been published on the association between IFNL4 rs368234815 single-nucleotide polymorphism (SNP) and sustained virological response (SVR) in chronic hepatitis C (CHC) patients undergoing treatment with PEGylated interferon (PEG-IFN) plus ribavirin (RBV).
|
27180197 |
2016 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
|
15865225 |
2005 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall treatment results of chronic hepatitis C have improved markedly with the introduction of pegylated interferon-alpha (PEG-IFN-alpha) and ribavirin combination therapy.
|
12798249 |
2003 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with chronic hepatitis C who are undergoing haemodialysis can be successfully treated with an escalating dosage regimen of PEG-IFN alpha-2b monotherapy.
|
19758272 |
2010 |